CD33 and cancer: In human cancer patients, MDSCs are identified as HLA-DR-CD11b+CD14-CD33+ cells that co-express the myeloid differentiation markers, CD11b and CD33, while lacking mature lymphoid and myeloid cell markers, such as HLA-DR, an MHC class II molecule (19).